Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60

Guggenheim analyst Brad Canino has maintained a Buy rating on Damora Therapeutics (NASDAQ: DMRA) and raised the price target from $40 to $60. This adjustment reflects a positive outlook on the company's performance.